XENOGENEIC CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) FOR MODULATION OF CETP ACTIVITY

Abstract: Methods for modulating cholesteryl ester transfer protein (CETP) activity and the plasma levels of lipoproteins involved in heart disease involve administration of a non-endogenous CETP or a plasmid-based vaccine for expression of such non-endogenous CETP to elicit production in a mammal of antibodies that recognize (bind to) the mammal's native (endogenous) CETP.

Description: XENOGENEIC CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) FOR MODULATION OF CETP ACTIVITY Cross-Reference to Related Application This application is a continuation-in-part application of United States Patent Application Serial No. 08/954,643, filed 20 October 1997. Field of the Invention This invention relates to the field of cardiovascular disease, particularly atherosclerosis. More particularly, the present invention provides compositions and methods for the control, treatment, or reduction of the risk of atherogenic activity in the circulatory system of mammals, particularly humans. Background of the Invention Cholesterol circulates through the body predominantly as a component of lipoprotein particles (lipoproteins), which are composed of a protein portion, called apolipoproteins (Apo) and various lipids, including phospholipids, triglycerides, cholesterol and cholesteryl esters. There are ten major classes of apolipoproteins: Apo A-I, Apo A-II, Apo-IV, Apo B- 48, Apo B-100, Apo C-I, Apo C-II, Apo C-III, Apo D, and Apo E. Lipoproteins are classified by density and composition. For example, high density lipoproteins (HDL), one function of which is to mediate transport of cholesterol from peripheral tissues to the liver, have a density usually in the range of approximately 1.063-1.21 g/ml. HDL contain various amounts of Apo A-I, Apo A-II, Apo C-I, Apo C-II, Apo C-III, Apo D, Apo E, as well as various amounts of lipids, such as cholesterol, cholesteryl esters, phospholipids, and triglycerides (TG). In contrast to HDL, low density lipoproteins (LDL), which generally have a density of approximately 1.019-1.063 g/ml, contain Apo B-100 in association with various lipids. In particular, the amounts of the lipids, cholesterol, and cholesteryl esters are considerably higher in LDL than in HDL when measured as a percentage of dry mass. LDL are particularly important in delivering cholesterol to peripheral tissues. Very low density lipoproteins (VLDL) have a density of approximately 0.95-1.006 g/ml and also differ in composition from other classes of lipoproteins both in their protein and lipid content. VLDL generally have a much higher amount of triglycerides than do HDL or LDL and are particularly important in delivering endogenously synthesized triglycerides from liver to adipose and other tissues. The features and functions of various lipoproteins have been reviewed (see, for example, Mathews and van Holde, Biochemistry, pp. 574-576 and 626-630 (The Benjamin/Cummings Publishing Co., Redwood City, California, 1990); Havel et al., "Introduction: Structure and metabolism of plasma lipoproteins", in The Metabolic Basis of Inherited Disease. 6th ed.. pp. 1129-1138 (Scriver et al., eds.) (McGraw-Hill, Inc., New York, 1989); Zannis et al., "Genetic mutations affecting human lipoproteins, their receptors, and their enzymes", in Advances in Human Genetics. Vol. 21. pp. 145-319 (Plenum Press, New York, 1993)). Decreased susceptibility to cardiovascular disease, such as atherosclerosis, is generally correlated with increased absolute levels of circulating HDL, with lowered levels of LDL or VLDL, and also with increased levels of HDL relative to circulating levels of VLDL and LDL (see, e.g., Gordon et al., N. Engl. J. Med., 321: 1311-1316 (1989); Castelli et al., J. Am. Med. Assoc, 256: 2835-2838 (1986); Miller, et al., Am. Heart J., 113: 589-597 (1987); Tall, J. Clin. Invest. 89: 379-384 (1990); Tall, J Internal Med., 237: 5-12 (1995)). Cholesteryl ester transport protein (CETP) mediates the transfer of cholesteryl esters from HDL to TG-rich lipoproteins such as VLDL and LDL, and also the reciprocal exchange of TG from VLDL to HDL (Tall, ibid.; Tall, J. LipidRes., 34: 1255-1274 (1993); Hesler et al, J. Biol. Chem., 262: 2275-2282 (1987); Quig et al., Ann. Rev. Nutr., 10: 169-193 (1990)). CETP may play a role in modulating the levels of cholesteryl esters and triglyceride associated with various classes of lipoproteins. A high CETP cholesteryl ester transfer activity has been correlated with increased levels of LDL-associated cholesterol and VLDL- associated cholesterol, which in turn are correlated with increased risk of cardiovascular disease (see, e.g., Tato et al., Arterioscler. Thromb. Vascular Biol, 15: 112-120 (1995)). CETP isolated from human plasma is a hydrophobic glycoprotein having 476 amino acids and a molecular weight of approximately 66,000 to 74,000 daltons on sodium dodecyl sulfate (SDS)-polyacrylamide gels (Albers et al., Arteriosclerosis, 4: 49-58 (1984); Hesler et al., J. Biol. Chem., 262: 2275-2282 (1987); jarnagin et al., Proc. Natl. Acad. Sci. USA, 84: 1854-1857 (1987)). A cDNA encoding human CETP has been cloned and sequenced (see, Drayna et al., Nature, 327: 632-634 (1987)). CETP has been shown to bind choesteryl esters, trygicerides, phospholipids (Barter et al., J. LipidRes., 21:238-249 (1980)), and lipoproteins (see, e.g., Swenson et al., J. Biol. Chem., 264: 14318-14326 (1989)). More recently, the region of CETP defined by the carboxyl terminal 26 amino acids, and in particular amino acids 470 to 475, has been shown to be especially important for neutral lipid binding involved in neutral lipid transfer (Hesler et al., J. Biol. Chem., 263: 5020-5023 (1988)). Hereinafter, LDL-C will be used to refer to total cholesterol, including cholesteryl esters and or unesterified cholesterol, associated with low density lipoprotein. VLDL-C will be used to refer to total cholesterol, including cholesteryl esters and/or unesterified cholesterol, associated with very low density lipoprotein. HDL-C will be used to refer to total cholesterol, including cholesteryl esters and/or unesterified cholesterol, associated with high density lipoprotein. A number of in vivo studies utilizing animal models or humans have indicated that CETP activity can affect the level of circulating cholesterol-containing HDL. Increased CETP cholesteryl ester transfer activity can produce a decrease in HDL-C levels relative to LDL-C and or VLDL-C levels which in turn is correlated with an increased susceptibility to atherosclerosis. Injection of partially purified human CETP into rats (which normally lack CETP activity), resulted in a shift of cholesteryl ester from HDL to VLDL, consistent with CETP -promoted transfer of cholesteryl ester from HDL to VLDL (Ha et al., Biochim. Biophys. Ada, 833: 203-211 (1985); Ha et al, Comp. Biochem. Physiol, 83B: 463-466 (1986); Gavish et al., J. Lipid Res., 28: 257-267 (1987)). Transgenic mice expressing human CETP were reported to exhibit a significant decrease in the level of cholesterol associated with HDL (see, e.g., Hayek et al., J. Clin. Invest., 90: 505-510 (1992); Breslow et al., Proc. Natl. Acad. Sci. USA, 90: 8314-8318 (1993)). Furthermore, whereas wild-type mice are normally highly resistant to atherosclerosis (Breslow et al., ibid.), transgenic mice expressing a simian CETP were reported to have an altered distribution of cholesterol associated with lipoproteins, namely, elevated levels of LDL-C and VLDL-C and decreased levels of HDL-C (Marotti et al., Nature, 364: 73-75 (1993)). Transgenic mice expressing simian CETP also were more susceptible to dietary-induced severe atherosclerosis compared to non-expressing control mice and developed atherosclerotic lesions in their aortas significantly larger in area than those found in the control animals and having a large, focal appearance more typical of those found in atherosclerotic lesions in humans (Marotti et al., ibid.). Intravenous infusion of anti-human CETP monoclonal antibodies (Mab) into hamsters and rabbits inhibited CETP activity in vivo and resulted in significantly increased levels of HDL-C, decreased levels of HDL-triglyceride, and increased HDL size; again implicating a critical role for CETP in the distribution of cholesterol in circulating lipoproteins (Gaynor et al., Atherosclerosis, 110: 101-109 (1994) (hamsters); Whitlock et al., J. Clin. Invest, 84: 129-137 (1989) (rabbits)). CETP deficiency has also been studied in humans. For example, in certain familial studies in Japan, siblings that were homozygous for non-functional alleles of the CETP gene had no detectable CETP activity. Virtually no atherosclerotic plaques were exhibited by these individuals, who also showed a trend toward longevity in their families (see, e.g., Brown et al., Nature, 342: 448-451 (1989); Inazu et al., N. Engl. J. Med., 323: 1234-1238 (1990); Bisgaier et al., J. LipidRes., 32: 21-23 (1991)). Such homozygous CETP-deficient individuals also were shown to have an anti-atherogenic lipoprotein profile as evidenced by elevated levels of circulating HDL rich in cholesteryl ester, as well as overall elevated levels of HDL, and exceptionally large HDL, i.e., up to four to six times the size of normal HDL (Brown et al., supra, p. 451). The frequency of this mutation in Japan is relatively high, and may account for an elevated level of HDL in a significant fraction of the Japanese population. The above studies indicate that CETP plays a major role in transferring cholesteryl ester from HDL to VLDL and LDL, and thereby in altering the relative profile of circulating lipoproteins to one which is associated with an increased risk of cardiovascular disease (e.g., decreased levels of HDL-C and increased levels of VLDL-C and LDL-C). Taken together, the current evidence suggests that increased levels of CETP activity may be predictive of increased risk of cardiovascular disease. Modulation or inhibition of endogenous CETP activity is thus an attractive therapeutic method for modulating the relative levels of lipoproteins to reduce or prevent the progression of, or to induce regression of, cardiovascular diseases, such as atherosclerosis. In our previous work, detailed, e.g., in commonly assigned, copending patent application PCT/US96/06147 (WO 96/34888) and commonly assigned copending patent application PCT/US97/07294 (WO 97/41227), both incorporated herein by reference, we detailed an approach for modulating the CETP activity in an individual via vaccination with a peptide composition or with a plasmid-based vaccine that would lead to the production of antibodies recognizing and neutralizing endogenous CETP. We demonstrated that administration of immunogenic peptides either by direct inoculation or by in situ production following injection of a functional plasmid-based vaccine resulted in production of antibodies reactive with the inoculated individual's own (endogenous) CETP. Thus the vaccine peptides and the plasmid-based vaccines break tolerance in the vaccinated individuals and to promote production of antibodies recognizing a self protein. Furthermore, administration of these vaccines to test animals resulted in a decline in the relative levels of total cholesterol and HDL-C and resulted in a decrease in the development of atherosclerotic lesions. The elicited endogenous anti-CETP antibodies thus promote a physiological condition correlated with decreased risk of cardiovascular disease, and they appear to have a direct effect on preventing or decreasing the formation of atherosclerotic plaques. We have now discovered another approach to eliciting the production of anti-CETP antibodies in a mammal. We have now determined that whole CETP molecules of another mammal, that is, non-endogenous CETP, can be used to elicit antibodies in a mammal that will be reactive with its own, endogenous CETP and serve to modulate the activity of CETP and to provide lowered circulating CETP activity, lowered total cholesterol, lowered circulating LDL levels, elevated ratios of HDL-C to LDL-C. The use of non-endogenous CETP to promote production of anti-endogenous CETP antibodies also leads to a reduction in development of atherosclerotic lesions in comparison to unvaccinated controls. Summary of the Invention Accordingly, the present invention provides compositions and methods useful for the modulation or inhibition of cholesteryl ester transfer protein (CETP) activity. In particular, the use of non-endogenous CETPs, including xenogeneic CETPs, is described as a means, when administered to a mammal, to raise an antibody response against the mammal's own endogenous CETP and thereby to promote a prophylactic or therapeutic effect against cardiovascular disease, such as atherosclerosis. Such non-endogenous CETP can be CETP of another mammalian species (xenogeneic CETP), such as rabbit CETP, mouse CETP or simian CETP for administration to a human; the non-endogenous CETP can be a non- endogenous allelic variation or polymorph of a mammalian CETP administered to the same species of mammal (e.g., a human CETP polymorph administered to another human); or the non-endogenous CETP can be a CETP from one species modified to have an amino acid sequence more similar to the native CETP of another species (e.g., a "humanized" rabbit CETP for administration to a human). Vaccine compositions and plasmid-based vaccines are described which, when suitably administered to a mammal result in the production of antibodies reactive with the mammal's endogenous CETP and the other benefits described herein. The invention provides methods for eliciting antibodies in a mammal that will be reactive with its own, endogenous CETP, for modulating the activity of CETP in a mammal, and for providing in a mammal lowered circulating CETP activity, lowered total cholesterol, lowered circulating LDL levels, and or elevated ratios of HDL-C to LDL-C. The invention provides a method for reducing or preventing in a mammal the development of atherosclerotic lesions. Brief Description of the Drawings Figure lA-C. An alignment of the amino acid sequences of mature rabbit CETP (SEQ ID NO: 3) with mature human CETP (SEQ ID NO: 1). The rabbit CETP is shown over the aligned human CETP sequence. The rabbit sequence includes 20 more amino acid residues than the human sequence, and the human sequence shows a 1 -amino acid and a 19- amino acid gap (indicated with dashes, — , in the human sequence) in order to show the residue matches (indicated with a vertical line, | ) most clearly. Figure 2. Shows the end point titers of antibodies from rabbit plasma recognizing the C-terminal peptide of rabbit CETP from rabbits vaccinated with human chorionic gonadotropin ("HCG Vaccine"), a synthetic vaccine peptide having segments of tetanus toxoid and the C-terminal sequence of human CETP ("Peptide Vaccine", see SEQ ID NO: 7), and full-length recombinant human CETP ("rhuCETP"). The figure shows maximum anti- CETP antibody titers achieved for each rabbit in an ELISA detecting plasma antibodies specific for rabbit CETP C-terminal peptide (amino acids 477-496). Figure 3. Shows inhibition of CETP activity in a commercial fluorescence-based assay (Roar Biomedical, Yonkers, New York) by protein A-isolated antibodies from the plasma of vaccinated rabbits from Groups I-III (see Examples, infra). The graph shows percent inhibition achieved in each of the vaccinated rabbits. Figure 4. Shows the CETP activity in the vaccinated rabbits from week 1 to week 32. Figure 5. Shows the percentage change in total cholesterol levels in the vaccinated rabbits from week 1 to week 12. Figure 6. Shows the HDL-associated cholesterol levels in the vaccinated rabbits from week 1 to week 32. Figure 7. Shows the percentage change in LDL-associated cholesterol levels in the vaccinated rabbits from week 1 to week 12. Figure 8. Shows the plasma lipoprotein levels for a rabbit vaccinated with non- endogenous CETP(recombinant human CETP, or rhuCETP). "V indicates the periodic vaccination boosts. HDL-associated cholesterol, total cholesterol level, and triglyceride level were assayed. Figure 9. Shows a correlation between CETP activity and HDL as a percent of total lipoproteins and total CETP mass, in a rabbit vaccinated with non-endogenous CETP (rhuCETP) Figure 10. Shows the levels of cholesterol deposits in the irises of 48 rabbits vaccinated with human chorionic gonadotropin ("HCG", rabbits #1-#12), a synthetic vaccine peptide having segments of tetanus toxoid and the C-terminal sequence of human CETP ("Peptide", see SEQ ID NO: 7, rabbits #13-#24), full-length recombinant human CETP ("rhuCETP", rabbits #25-#36), and a CETP-tetanus toxoid conjugate composition.("Conjugate", rabbits #37-#48). The irises of each rabbit have been scored based on the percentage of deposits observed from 0-5, 0 representing no deposits and 5 representing 100% deposits observed in the iris of the animal. Figure 11. Shows percentage of the aorta covered by lesions observed in vaccinated rabbits fed an atherogenic diet. Values of individual animals are represented by open symbols. Figure 12. Shows anti-CETP antibody titers for mice vaccinated with various plasmid-based vaccines. Figure 13A-K. Shows antibody titers of 1 1 rabbits vaccinated with pSV40-HuCETP between weeks 1-32. The open diamond and open square symbols refer to the antibody titers of the rabbits on weeks 30 and 34 respectively. Figure 14. Shows the effect of plasmid vaccination on the development of aortic lesions. The figure compares the mean percentages collected for control rabbits (pSV40 plasmid without the CETP coding sequence) and rabbits vaccinated with pSV40-huCETP. Detailed Description of the Invention As noted above, a decreased risk of atherosclerosis has been correlated with relatively low circulating levels of LDL and VLDL and relatively high levels of HDL. The levels of such circulating lipoproteins are directly influenced, at least in part, by the endogenous levels of CETP activity. In particular, high CETP activity promotes transfer of neutral lipids, such as cholesteryl esters from HDL to VLDL and LDL. Accordingly, CETP is a relatively precise target in humans and other animals for altering the relative levels of LDL, VLDL and HDL in the circulatory system (see, e.g., Tato et al., Arteriosclero. Thromb. Vascular Biol, 15: 1 12-120 (1995); Tall, J. Internal Med, 237: 5-12 (1995)). This invention is directed to the control of endogenous CETP activity by providing non-endogenous CETP molecules to an individual, for promoting an immune response in such individuals against their endogenous CETP, thereby promoting a physiological condition (e.g., increased level of HDL or decreased level of LDL) correlated with a decreased risk of atherosclerosis. In addition, promoting an immune response against endogenous CETP using the vaccine compositions of this invention can provide, prevent, or inhibit the progression of lesions in tissue susceptible to atherosclerosis. Compositions for Modulation of CETP Activity As used herein, a CETP vaccine composition for use according to the invention contains as an essential ingredient a CETP or a portion thereof, that is non-endogenous with respect to the mammal to be vaccinated. For the purposes of this invention, "non-endogenous CETP" means a cholesteryl ester transfer protein that is not the native CETP produced by the mammal to be vaccinated. For example, with respect to a human subject, non-endogenous CETP will include CETP produced by another mammalian species, i.e., xenogeneic CETP, such as rabbit, mouse or simian CETP; or non-endogenous CETP with respect to a particular human subject can be an allelic variant or polymorphism of human CETP, such as CETP produced by another human individual. The non-endogenous CETP can also be a xenogeneic CETP that has been modified in order to make the amino acid sequence of the modified CETP more similar to that of the endogenous CETP of the mammal to be vaccinated. The term used herein to describe such modified non-endogenous CETP is "mammalianized CETP". This term is used with reference to the mammal to be vaccinated, and it means a non-endogenous CETP that has been modified to have an amino acid content more similar to the native CETP of said mammal. An example of a mammalianized CETP, where the subject to be vaccinated is a human, would be a rabbit CETP modified (or "humanized") to have an amino acid sequence more similar to the native human sequence. As a further example, reference is made to Figures 1 A, IB and 1C, which show the respective amino acid sequences of rabbit CETP (SEQ ID NO: 3) and human CETP (SEQ ID NO: 1) in alignment. Referring to Figures 1A-1C, it is seen that the structure of these two mammalian CETPs is similar, having the same amino acids at 80% of the positions of human CETP. Rabbit CETP (SEQ ID NO: 3) is 20 amino acids longer than human CETP (SEQ ID NO: 1), and the alignment of the two proteins in Figures 1A-1C shows two segments, denoted with dashes ( — ), where the proteins do not correspond structurally. With respect to a human subject to be administered a non-endogenous CETP in accordance with this invention, an example of a "mammalianized" non-endogenous CETP would be a rabbit CETP in which the 19-amino acid segment from amino acid Ala 393 through Ala 4I I of rabbit CETP has been deleted, making the modified CETP (see SEQ ED NO: 5) 477 amino acids in length and thus more similar to the human CETP (SEQ D NO: 1). Since the mammal of this example is a human, another term for such a modified CETP or mammalianized non-endogenous CETP would be a "humanized rabbit CETP". Again referring to Figures 1A-1C, a further example of a humanized rabbit CETP would be a CETP as set forth in SEQ ID NO: 6. In Figure 1C it is noted that in the C- terminal portion of the human and rabbit CETPs there is only one difference in the respective amino acid sequences, i.e., Lys 485 of the rabbit CETP corresponds to Glu 465 in the human CETP. In practicing the methods of the present invention, non-endogenous CETP is administered to a mammal in an amount effective to elicit an immune response. As is common in the field, more than one administration may be necessary or desirable to obtain a high enough concentration of anti-endogenous CETP antibodies in the mammal to affect endogenous CETP activity. Immunogenicity of a vaccine peptide of this invention may be further enhanced by linking the immunogenic non-endogenous CETP to itself or to a related protein homologous to CETP. In this approach, a dimer could be formed, with the dimer providing a multi-chain protein that is even more immunogenic than the non-endogenous CETP alone. Examples of proteins related to CETP that might be used in this approach include, for example, phospholipid transfer protein and neutrophil bactericidal protein (see, Day et al., J. Biol. Chem., 269: 9388-91 (1994); Gray et al., J. Biol. Chem., 264: 9505-9509 (1989)). Other immunogenic carrier molecules such as keyhole limpet hemocyanin (KLH) may also be used in combination with the non-endogenous CETP. For example, KLH contains multiple lysine residues in its amino acid sequence. Each of these lysines is a potential site at which a CETP molecule as described herein could be linked (for example, using maleimidc activated KLH, Catalog No. 77106, Pierce, Rockford, IL), to provide a multivalent non- endogenous CETP immunogen. Another example of an immunogenic carrier molecule is hsp70 from Mycobacterium tuberculosis, which has been shown to be an especially potent antigen containing multiple B and T cell epitopes (see, e.g., Suzue and Young, J. Immunol, 156: 873 - 879 (1996)). The hsp70 protein can be linked by standard cross-linking agents to non-endogenous CETPs to enhance immunogenicity of the vaccine compositions. Other peptides can be conjugated with the non-endogenous CETP molecules to provide a source of helper T cell epitopes and boost the immunogenicity of the vaccine compositions according to the invention. Such peptides include, for example, "universal" anti genie peptides, e.g., tetanus toxoid or diphtheria toxoid, especially the tetanus toxoid fragment: Gin Tyr He Lys Ala Asn Ser Lys Phe He Gly He Thr Glu (amino acids 2 to 15 of SEQ ED NO: 7). Pharmaceutically acceptable adjuvants, such as alum, may be mixed with the non- endogenous CETPs described herein to produce vaccine compositions of this invention. Alum is the single adjuvant currently approved for use in administering vaccines to humans (see, Eldrige et al., in Immunobiology of Proteins and Peptides V: Vaccines: Mechanisms. Design, and Applications (Atassi, M.Z., ed.)(Plenum Press, New York, 1989), page 192). Alum in combination with a sodium phthalyl derivative of lipopolysaccharide can also be used (see, Talwar et al., Proc. Natl Acad. Sci. USA, 91 : 8532-8536 (1994)). Other conventional adjuvants may be used as they are approved for a particular use. For example, biodegradable microspheres comprised of poly (DL-lactide-co-glycolide) (Eldridge et al., supra, pp. 191-202); Freund's Complete Adjuvant (Sigma Chemical Co., St. Louis, Missouri), Freund's Incomplete Adjuvant (Sigma Chemical Co., St. Louis, Missouri), and the REBI™ Adjuvant System (RAS; REBI ImmunoChem Research, Inc., Hamilton, Montana); lipophilic N-palmitoyl-S-[2,3-bis(palmitoyloxy)-propyl)]-cysteine ("Pam 3 -Cys-OH"); amphiphilic, water-soluble lipopeptides such as Pam 3 -Cys-Ser-Lys 4 and Pam 3 -Cys-Ser-Glu 4 ; glycopeptides such as N-acetyl-glucosaminyl-N-acetylmuramyl-alanyl-D-isoglutamine ("GMDP"), muramyl dipeptides, and alanyl-N-adamantyl-D-glutamine; and polyamide gel- based adjuvants which can easily be attached to CETP peptides during their in vitro chemical synthesis (see, Synthetic Vaccines (Nicholson, ed.) (Blackwell Scientific Publications, Cambridge, Massachusetts, 1994), pp. 236-238). Where helper T cell epitope molecules or adjuvant species are to be physically linked or conjugated with the non-endogenous CETP, the CETP can be covalently linked directly or via a cross-linker molecule. Suitable cross-linking molecules include amino acids, for example, using one or more glycine residues to form a "glycine bridge" between the CETP and the carrier or adjuvant molecule. Also contemplated are the formation of disulfide bonds between cysteine residues, or the use of cross-linking molecules such as glutaraldehyde (see, Korn et al., J. Mol Biol, 65: 525-529 (1972)) and EDC (Pierce, Rockford, IL) or other bifunctional cross-linker molecules. Bifunctional cross-linker molecules possess two distinct reactive sites; one of the reactive sites can be reacted with a functional group on the CETP and the other reactive site can be reacted with a functional group on the carrier or adjuvant molecule, uniting the two. General methods for cross-linking molecules are reviewed by Means and Feeney (Bioconjugate Chem., 1: 2-12 (1990)). Homobifunctional cross-linker molecules have two reactive sites which are chemically the same. Examples of homobifunctional cross-linker molecules include glutaraldehyde; N,N'-bis(3-maleimido-propionyl)-2-hydroxy-l,3-propanediol (a sulfhydryl- specific homobifunctional cross-linker); certain N-succinimide esters, such as disuccinimidyl suberate and dithio-bis-(succinimidyl propionate) and their soluble bis-sulfonic acids and salts (e.g., as available from Pierce Chemicals, Rockford, Illinois; or Sigma Chemical Co., St. Louis, Missouri). Preferably, the bifunctional cross-linker molecule is a heterobifunctional linker molecule, meaning that the linker molecule has at least two reactive sites that can be separately covalently attached to the non-endogenous CETP and the carrier or adjuvant molecule. Heterobifunctional cross-linker molecules that may be used include m- maleimidobenzoyl-N-hydroxysuccinimide ester; m-maleimido-benzoylsulfosuccinimide ester; γ-maleimidobutyric acid N-hydroxysuccinimide ester; and N-succinimidyl 3-(2- pyridyl-dithio)propionate. The non-endogenous CETP for use according to this invention can be produced by any of the available methods known in the art to produce proteins of defined amino acid sequence. For example, automated peptide synthesis is available to those skilled in the art by using automated peptide synthesizers (e.g., Synergy™ Peptide Synthesizer by Applied Biosystems; AMS 422 by Abimed, Langenfeld, Germany). Synthesis of such proteins to order is performed as a commercial service by many commercial peptide synthesizing service companies, e.g., Quality Controlled Biochemicals, Inc., (Hopkinton, Massachusetts); Chiron Mimotopes Peptide Systems (San Diego, California); Bachem Bioscience, Inc. (Philadelphia, Pennsylvania); Severn Biotech Ltd. (Kiddeminster, England). Alternatively, the proteins of this invention may be produced using synthetic and recombinant nucleic acid technology. For example, one of ordinary skill in the art can design from the known genetic code a 5' to 3' nucleic acid sequence encoding a proteins of this invention. The amino acid sequence for a mature human CETP is known (SEQ ID NO: 1), as well as its corresponding DNA sequence (SEQ ED NO: 2) (see, Drayna et al., Nature, 327: 632 - 634 (1987)). Furthermore, the amino acid sequence for a mature rabbit CETP is known (SEQ ID NO: 3), as well as its corresponding DNA sequence (SEQ ID NO: 4) (see, Nagashima et al., J. Lipid. Res., 29: 1643 - 1649 (1988)). A DNA molecule containing the coding sequences of desired CETP (or a modified "mammalianized" CETP as described above) can readily be synthesized either using an automated DNA synthesizer (e.g., Oligo 1000 DNA Synthesizer, Beckman Corp.) or by contracting with a commercial DNA synthesizing service (e.g., Genset Corp., La Jolla, California). The synthesized or cloned DNA molecule can then be inserted into any of a variety of available gene expression systems (e.g., bacterial plasmids; bacteriophage expression vectors, retroviral expression vectors, baculoviral expression vectors), using standard methods available in the art (e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual. Vols. 1- 3 (Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1989)) and/or as directed by the manufacturer of a particular commercially available gene expression system (e.g., pPROEX™-l bacterial cell expression system; SFV eukaryotic cell expression system; CHO (Chinese Hamster Ovary cells) expression system; BAC-TO-BAC™ baculovirus expression system; Life Technologies, Inc., Gaithersburg, Maryland). Especially preferred for the expression of CETP is the CHO expression system. The expressed CETP can then be isolated from the expression system using standard methods to purify proteins. Purification of the non-endogenous CETPs of this invention may be expedited by employing affinity chromatography or immunoprecipitation based on using antibodies to the particular CETP domain. For example, the Mab TP2 (Hesler et al., J. Biol. Chem., 263: 5020-5023 (1988)) binds to the carboxyl terminal 26 amino acids of human CETP, and could be useful in one or more immunoaffinity steps in a purification scheme. Another method that could be used in the purification of the proteins is standard column chromatography (Weinberg et al., J. Biol. Chem., 269: 29588-29591 (1994)). The non-endogenous CETPs as described herein are used to make vaccines compositions that elicit, when administered to a mammal, production of endogenous antibodies which specifically bind to endogenous CETP of the mammal and/or modulate (i.e., decrease or inhibit) endogenous CETP activity in the mammal. The anti-CETP vaccine compositions of this invention may contain one or several different non-endogenous CETPs. In addition, the non-endogenous CETP may be linked to other molecules that may enhance the immunogenicity of the peptides. The vaccine compositions for administration of non-endogenous CETP according to this invention can also advantageously take the form of plasmid-based vaccines for producing non-endogenous CETP in situ, eliciting autoantibodies directed to endogenous CETP. Such plasmid-based vaccines are, specifically, DNA plasmids which are administered (for example, by intramuscular injection or intradermal ballistic administration) to an individual. The administered DNA plasmids encode and direct the production of immunogenic non- endogenous CETP. We have discovered that such immunogenic CETP elicits the production of autoantibodies that react specifically with (i.e., bind to) endogenous CETP in the individual. An example of a recombinant plasmid that can be used to produce a non-endogenous CETP for use according to this invention is plasmid pCMV-CETP/TT in which the CMV promoter directs transcription of a sequence encoding a vaccine peptide described in the previously mentioned PCT/US96/06147. E. coli bearing plasmid pCMV-CETP/TT has been deposited with the American Type Culture Collection (ATCC, Rockville, MD) and assigned Accession No. 98038. DNA coding for a desired CETP can be inserted in place of the vaccine peptide coding sequence in pCMV-CETP/TT and used for the expression of full- length CETP molecules. The production of anti-CETP antibodies promotes a physiological state associated with a decreased risk of cardiovascular disease. The beneficial modulation of CETP activity produced by the DNA vaccines is evidenced by a significantly decreased or eliminated CETP activity; by an anti-atherogenic lipoprotein profile (for example, an increase in the level of HDL or HDL-C compared to LDL, LDL-C, VLDL, or VLDL-C); or by an inhibition -13- (including prevention) or decrease in the development of atherosclerotic lesions in cardiovascular tissue, such as the aorta. General methods of administering and testing vaccines are well known to those skilled in the art (see, e.g., Talwar et al, Proc. Natl Acad. Sci. USA, 91 : 8532-8536 (1994)). The immune response to endogenous CETP should significantly inhibit CETP activity, alter the serum half- life of CETP, cause clearance CETP through formation of immune complexes,, alter the trafficking of HDL-cholesterol, shift the equilibrium of cholesterol content of lipoproteins, alter cholesterol catabolism, and/or reduce development of atherosclerotic lesions. Control of LDL, VLDL and/or HDL levels is an accepted indicator or endpoint in treatment of cardiovascular disease, as these levels are correlated with a decreased risk of cardiovascular disease or further progression of such disease (see, e.g., Mader, in Human Biology. 4th ed.. pp. 83, 102 (Wm. C. Brown Publishers, Dubuque, Iowa, 1995)). Accordingly, the desired prophylactic or therapeutic effect according to this invention is evidenced by eliciting antibodies in an individual that bind to endogenous CETP and/or inhibit endogenous CETP activity, or by a relative decrease in LDL and/or VLDL levels compared to HDL levels as the titer of antibody directed against the endogenous CETP rises, or by a decrease of absolute levels of circulating LDL and/or VLDL with the production of anti-CETP antibodies, or by an inhibition or decrease in development of atherosclerotic lesions in cardiovascular tissue. As demonstrated herein, administration of non-endogenous CETP in a rabbit model of atherosclerosis led to a significant decrease in the development of atherosclerotic plaques. This evidence indicates that vaccination to elicit antibodies to endogenous CETP may be a useful method of treating or preventing atherosclerosis. The successful use of non-endogenous CETP to elicit anti-endogenous CETP antibodies and to modulate the activity of native CETP was surprising in a number of respects. Previously, the use of whole CETP molecules had been avoided, since it was not known whether introduction of a whole, non-endogenous CETP molecule would provide the desired immunogenic effects. For example, non-endogenous CETP might function perfectly well as a CETP and exacerbate already undesirable cholesterol levels and metabolism. In addition, it was contemplated that full-length CETP molecules might contain immunogenic segments that would elicit antibodies capable of reacting or interfering with proteins or receptors outside of the CETP metabolic pathway, resulting in dangerous cross-reactions or side-effects. Finally, it was not known whether introduction of a non-endogenous CETP would be able to break tolerance in the subject vaccinated, leading to production of antibodies reactive not with (or not only with) the non-endogenous CETP but with the native CETP. These uncertainties have now been resolved. The non-endogenous CETP vaccine compositions may be administered by any route used for vaccination, including: parenterally such as intraperitoneally, interperitoneally, intradermally, subcutaneously, intramuscularly, intravenously or orally. Preferably, the vaccines of this invention are administered parenterally, e.g., intraperitoneally, interperitoneally, subcutaneously, intradermally, intramuscularly, or intravenously. If oral administration of a vaccine peptide is desired, any pharmaceutically acceptable oral excipient may be mixed with the vaccine peptides of this invention, for example, such as solutions approved for use in the oral polio vaccine. As with certain other vaccines, such as for tetanus, an occasional booster administration of the CETP vaccine compositions may be necessary to produce or maintain a desired level of modulation or inhibition of endogenous CETP. Biodegradable microspheres, such as those comprised of poly (DL-lactide-co-glycolide), have been shown to be useful for effective vaccine delivery and immunization via oral or parenteral routes. Appropriate dosages of the non-endogenous CETP may be established by general vaccine methodologies used in the art based on measurable parameters for which the vaccine is proposed to affect, including monitoring for potential contraindications, such as hypersensitivity reaction, erythema, induration, tenderness (see, e.g., Physician's Desk Reference. 49th ed.. (Medical Economics Data Production Co., Mont Vale, New Jersey, 1995), pp. 1628, 2371 (referring to hepatitis B vaccine), pp. 1501, 1573, 1575 (referring to measles, mumps, and/or rubella vaccines), pp. 904, 919, 1247, 1257, 1289, 1293, 2363 (referring to diphtheria, tetanus and/or pertussis vaccines)) ; Talwar, G.P., et al., Proc. Natl. Acad. Sci. USA, 91: 8532-8536 (1994)). A common and traditional approach for vaccinating humans is to administer an initial dose of a particular vaccine to sensitize the immune system and then follow-up by one or more "booster" doses of the vaccine to elicit an anamnestic response by the immune system that was sensitized by the initial administration of the vaccine (vaccination). Such a "primary and booster" administration procedure has been well known and commonly used in the art, as for example, in developing and using measles, polio, tetanus, diphtheria, and hepatitis B vaccines. Initially, the amount of a vaccine composition administered to an individual may be that required to neutralize the approximate level of endogenous CETP activity present in the individual prior to vaccination, as can be determined by measuring CETP activity in serum or plasma samples from the individual, for example as determined using a commercially available CETP assay (e.g., Roar Biomedical., Yonkers, New York). Plasma or serum samples from a vaccinated individual can also be monitored to determine whether a measurable increase in the levels of total HDL or HDL-C is seen after administration of the non-endogenous CETP using commercially available assays (e.g., available from Sigma Diagnostics, Inc., Saint Louis, Missouri). A rise in the concentration (titer) of circulating anti-CETP antibodies can be measured in plasma or serum samples, for example using an ELISA assay. Thus, it is possible and recommended that initially it be established whether a rise in anti-CETP antibody can be correlated with an increase in the level of HDL or HDL-C, a decrease in LDL or VLDL, or with a decrease in CETP activity. Thereafter, one need only monitor a rise in titer of anti-CETP antibody to determine whether a sufficient dosage of vaccine peptide has been administered or whether a "booster" dose is indicated to elicit an elevated level of anti-CETP antibody. This is the common procedure with various established vaccinations, such as vaccination against hepatitis B virus. Three-dimensional arterial imaging methods are currently available which can be used to identify arterial lesions and monitor their development or regression in an individual (see, for example, McPherson, Scientific American Science & Medicine, pages 22-31 , (March April, 1996)). Thus such imaging methods can be used to monitor the effectiveness of vaccination according to the methods of this invention. A more complete appreciation of this invention and the advantages thereof can be obtained from the following non-limiting examples. EXAMPLE 1 Immunization of Rabbits Against Endogenous CETP Four vaccine preparations were made for injection into four groups of twelve New Zealand White Rabbits, to test the ability of the vaccine preparation to elicit an immune response against endogenous rabbit CETP. Group I (negative control) contained rabbits #1 - #12, each of which was injected with a vaccine composition contaimng an irrelevant antigen, human chorionic gonadotropin (hCG). Group II (comparative embodiment of PCT/US96/06147) contained rabbits #13 - #24, each of which was injected with a vaccine peptide having a portion of the C-terminus of human CETP and a portion of tetanus toxoid ("Peptide"; see, SEQ ID NO: 7). Group III (this invention) contained rabbits #25 - #36, each of which received a vaccine composition containing whole recombinant human CETP ("rhuCETP"). Group IV (this invention) contained rabbits #37 - #48, each of which received a vaccine composition containing whole recombinant human CETP conjugated with whole tetanus toxoid using a chemical crosslinker ("Conjugate"). The general protocol for vaccinating and testing the rabbits was as follows: On Day 1, each rabbit received one subcutaneous injection of a composition containing 200 μg of immunogen in Complete Freund's Adjuvant (Sigma Chemical Co., St. Louis, Missouri). Each composition suspended the respective immunogen in phosphate buffered saline (PBS) and emulsified with complete Freund's adjuvant (1 : 1) to yield a final concentration of 100 μg/100 μl. Each rabbit was administered the vaccine mixture in a 200 μl dose (200 μg immunogen) at one subcutaneous site. A boost of 200 μg of immunogen in Incomplete Freund's Adjuvant (Sigma Chemical Co.) was administered as on Day 1 at Day 28 and Day 49. Blood samples (approximately 1-5 ml) were withdrawn from the ear of each rabbit (prior to injections) on Days 1 ("prebleed"), 28 , 49, 105, 147 and 217. Blood plasma samples were prepared by standard centrifugation methods to separate cellular components from the plasma. Plasma samples were stored at -70° C. Plasma samples of both Groups I and II were analyzed for presence of and increase in titer of anti-CETP antibodies and for CETP activity, CETP mass, and plasma levels of various lipoprotein components (HDL, LDL, triglycerides). Direct ELISA for Titering Anti-CETP Antibodies A sandwich enzyme-linked immunosorbent assay (ELISA) was used to titer plasma samples containing anti-CETP antibody. A biotinylated C-terminal peptide (20 amino acids) of rabbit CETP was adsorbed to wells of a microtiter dish coated with streptavidin, and various dilutions of rabbit plasma from the rabbits of Groups I - III were added to each well. Non-specific binding can be blocked by adding a 1% solution of BSA in PBS and 0.05% Tween to each well and incubating for 2 hours at room temperature (20 -22° C) on a rotating shaker at 150 rpm. The wells were then washed four times with ELISA wash buffer (PBS + 0.05%) Tween). Plasma samples were then diluted in dilution buffer (e.g.1 % BSA in PBS), followed by serial dilutions in the same buffer. Diluted samples (100 μl) were added to the wells, incubated for 1.5-2 hours at room temperature on a rotating shaker at 150 rpm, and then washed 4 times with ELISA wash buffer (PBS + 0.05% Tween). To detect bound anti CETP antibodies, 100 μl of an optimized dilution of horseradish peroxidase (HRP) labeled goat anti-rabbit immunoglobulin (Southern Biotechnology Associates, Inc.; Birmingham, Alabama; or Jackson Immunoresearch, Inc.; West Grove, Pennsylvania) in dilution buffer was added, and the plates were incubated for 2 hours at room temperature on a rotating shaker at 150 rpm. The wells were then washed four times with ELISA wash buffer (see above), peroxidase substrate TMB (TMB peroxidase substrate, Kirkegaard & Perry Laboratories, Inc., Gaithersburg, Maryland) was added, and the plates were incubated 30 minutes at room temperature. Change in optical density was monitored spectrophotometrically at 450 nm using an ELISA reader (e.g., E-max, Molecular Device Corp., Menlo Park, California). In this assay, the O.D. was directly proportional to the amount of anti-CETP antibodies present in the plasma samples. The results of the assay for each of the rabbit groups is shown in Figure 2. Group I showed no plasma antibodies detecting the rabbit C-terminal CETP peptide, whereas the groups vaccinated with CETP immunogens (Groups II, III) showed significant titers of anti- CETP antibodies in almost all vaccinated rabbits. Analysis of the Group IV data is in progress. CETP Activity and Neutralization Assays In order to measure the activity of CETP in plasma, a commercial fluorescence-based assay (Roar Biomedical Inc.; Yonkers, New York) was used. Incubation of a CETP source (rhuCETP, huCETP or rabbit CETP) with the donor and acceptor particles, included in the kit, results in the CETP -mediated transfer of a fluorescent neutral lipid. This fluorescent neutral lipid is present in a self-quenched state when contained within the core of the donor. The CETP-mediated transfer is determined by the increase in fluorescence intensity as the fluorescent neutral lipid is removed from the self-quenched donor to the acceptor. To measure neutralization, anti-CETP antibodies are isolated from the plasma of vaccinated rabbits with protein A. Identical amounts (measured by A280) of the antibodies from various samples are added to the above reaction. Figure 3 shows inhibition of CETP activity by rabbit antibodies collected from the plasma of the vaccinated rabbits. The bar designated "Positive Control Mab" refers to anti- CETP monoclonal antibody TP2, which is known to inhibit CETP activity in vitro and is included for comparison. Figure 4 shows the change in CETP activity in Groups I and III from week 1 to week 32. Analysis of the Group IV data is in progress. Cholesterol and HDL Levels in Plasma Samples of Vaccinated Rabbits The plasma samples taken from rabbits of Groups I - FV were also assayed for the concentration of total cholesterol (Figure 5), HDL-C (Figure 6), and triglycerides (see Figure 8) using standard commercial assays (Sigma Diagnostics, Inc., Saint Louis, Missouri). LDL- C (Figure 7) is calculated as total cholesterol minus HDL-C minus 0.2 x tryglyceride level. CETP levels were determined by a slot blot analysis using anti-CETP monoclonal antibody TP2 and chemiluminescences for detection. The band intensities obtained with various amounts of plasma samples were quantified with the aid of a Kodak® DC40 camera and ID Image Analysis software (version 1.6), then compared to that obtained with known amounts of purified human CETP loaded on the same nitrocellulose filter. The plasma lipoprotein profile for the Group III rabbit #32, which showed the most pronounced reduction in LDL-C levels (Fig. 7) is shown in Figure 8. The profile shows a dramatic rise in HDL as a percent of the total lipoprotein profile. Figure 9 shows, for this rabbit, the correlation between decreasing CETP activity, decreasing cholesterol mass and increasing HDL as a percentage of total lipoportein. Measurement of cholestrol deposits in the irises of vaccinated rabbits The rabbits from Groups I - IV were also assayed for the amount of cholestrol deposits detected in the irises. A scale of cholestrol deposition in the iris was established, with 0 = no deposit, 1 = 20%, 2 = 40%, 3 = 60%, 4 = 80%, and 5 = 100% deposits on this iris (i.e., iris completely covered with deposits). One iris per rabbit was evaluated and scored for degree of cholestrol deposition. The groups of animals were blinded to the scorer to avoid bias. Figure 10 shows the data collected from all 48 animals. The Xs indicate animals for which no data were obtained (rabbit #34, #39, and #42); these animals were euthanized due to unrelated complications such as furballs. The data indicate that all CETP vaccinated groups had statistically less cholestrol deposits than the control group. Ouantitation of lesions in aorta of vaccinated rabbits The rabbits were switched from a diet of basic rabbit chow to diets supplemented with 0.25% cholesterol (w/w) known to produce atherosclerotic-like lesions in rabbits (Daley et al., Arterioscler. Thromb., 14: 95 - 104 (1994)). To determine whether the vaccination may affect the development of atherosclerosis, the aortas of these rabbits were examined for the development of atherosclerotic lesions. After blood samples were taken on the last day, rabbits were sacrificed. The entire aortas from each of Groups I-IV were removed and placed into fixative solution (3.7 % v/v formaldehyde). Loose tissue, adherent fat, and the adventitia were dissected free from the arteries. Each artery was then cut lengthwise, pinned flat to expose the intimal (luminal) surface, stained with Sudan FV, and then photographed. Sudan IN is a fat soluble red dye that stains atherosclerotic plaques on the intimal surface of arteries. Figure 11 summarizes the results of this experiment. The stained aortas of rabbits vaccinated with human chorionic gonadotropin ("HCG") revealed a prevalence of atherosclerotic lesions along the length of the aortas and particularly in the portion of the aortas from the thoracic region. In contrast, the aortas of rabbits vaccinated with a synthetic vaccine peptide having segments of tetanus toxoid and the C-terminal sequence of human CETP ("Peptide", see SEQ ID NO: 7), full-length recombinant human CETP ("rhuCETP"), and a CETP-tetanus toxoid conjugate composition ("Conjugate") had lower incidence of lesions, including the portion of the aorta from the thoracic region. To quantitate the noticeable difference in the presence of atherosclerotic lesions in the aortas of rabbits or lack thereof, the total surface area of the pinned aortas and that of the aortic lesions was determined from photographs by planar morphometry (Daley et al., 1994) using a digitizing tablet with associated software (THE MORPHOMETER™, Woods Hole Educational Associates, Woods Hole, Massachusetts). The percentage of the surface area of the aortas covered by lesions was determined and the percentages are represented in Figure 11. EXAMPLES 2 and 3 Plasmid-based Vaccines in Mice and Rabbits Four groups of mice were vaccinated intramuscularly with one of the following: 1. pCMV: a plasmid vector having the cytomegalovirus immediate early promoter/enhancer but without any operably-linked structural gene 2. pCIII-huCETP: a plasmid vector having the full coding sequence for human CETP (SEQ ID NO: 1) under the transcriptional control of the human Apo CIII promoter 3. pSV40-huCETP: a plasmid vector having the full coding sequence for human CETP under the transcriptional control of the SV40 promoter 4. pCMV-TT-rabCETP: a plasmid vector having a tetanus toxoid peptide (amino acid ; 2 to 15 of SEQ ED NO: 7) coding sequence and the full coding sequence for rabbit CETP (SEQ ID NO: 3) under the transcriptional control of the cytomegalovirus immediate early promoter/enhancer The mice were injected once with 25 μl of PBS containing 100 μg of the plasmid and blood samples were periodically collected and were analyzed with an ELISA detecting anti- human CETP antibodies with the method described below: Plastic 96-well microtiter plates were coated with Protein A/G, by incubating 100 μl of a 5 μg/ml PBS solution per well overnight at 4°C. The plates were emptied and the wells were blocked with 200 μl of blocking buffer (PBS with 4% BSA, 1% sucrose, 0.5% NP-40, 0.01%) Gentamycin) for 2 to 8 hours at room temperature. Antibodies from the plasma samples were captured on the Protein A/G by incubating 100 μl of various dilutions of the samples for 1 hour at room temperature. Following washing of the wells, biotinylated CETP was captured by the plate bound antibodies by incubating 100 μl of a biotinylated CETP solution at room temperature for 1 hour. The bound CETP was detected by incubating 100 μl of a streptavidin-HRP solution for 30 minutes at room temperature, followed by adding 100 μl of substrate, stopping the reaction with 0.18M sulfuric acid and reading the optical density at 450 nm. Figure 12 shows that plasmids delivered to Groups 2, 3, and 4 produce immunogenic xenogeneic protein. Subsequently, rabbits were vaccinated with 300 μg (equally split in six intramuscular sites in the quadriceps) of a vector carrying the human CETP coding sequence under the transcriptional control of the SV40 promoter enhancer (SV40-huCETP) or the same vector without the CETP coding sequence (SV40). The primary injection occurred on Day 1 with an identical boost on weeks 5, 8, 26, and 30. Blood samples were taken periodically throughout the experiment and animals were terminated on week 34. The plasma samples from the vaccinated rabbits were subjected to the ELISA for detection of antibodies to whole recombinant human CETP, as described above. Figure 13A-K summarizes the titration of the antibody measured in the rabbits vaccinated with the SV40 promoter enhancer (SV40-huCETP) between weeks 1-34. Significant antibody production was detected on weeks 30 and 34, depicted by the open diamond and open square symbols of the graphs, in most animals. Two of the 11 rabbits (Figure 13 A, and 13E) were non-responders. The rabbits were switched from a diet of basic rabbit chow to diets supplemented vith 0.25% cholesterol (w/w) known to produce atherosclerotic-like lesions in rabbits. The lesions in rabbits vaccinated with pSV40-huCETP and control rabbits vaccinated with pSV40 were visualized and quantitated as described in Example 1 above. Figure 14 shows the mean percentage of aorta covered with lesions in both groups of rabbits. The results of this experiment are in line with the trend observed with directly vaccinated rabbits (Groups I-IV, see Figure 11), showing a decrease in aortic lesions due to vaccination. Although a number of embodiments have been described above, it will be understood by those skilled in the art that modifications and variations of the described compositions and methods may be made without departing from either the spirit of the invention or the scope of the appended claims. The articles and publications cited herein are incorporated by reference.

Claims: CLAIMS: 1. A vaccine composition effective to promote production of antibodies binding to endogenous cholesteryl ester transfer protein (CETP) in a mammal, consisting essentially of a non-endogenous CETP, optionally in combination with an adjuvant effective to non- specifically stimulate the immune response of said mammal. 2. A vaccine composition as defined in Claim 1, wherein said mammal is a human and said non-endogenous CETP is selected from the group consisting of rabbit CETP, mouse CETP, simian CETP, humanized rabbit, mouse or simian CETP, and allelic variants or polymorphs of said human's CETP. 3. A vaccine composition effective to promote production of antibodies binding to endogenous cholesteryl ester transfer protein (CETP) in a mammal, consisting essentially of a mammalianized non-endogenous CETP, optionally in combination with an adjuvant effective to non-specifically stimulate the immune response of said mammal. 4. A vaccine composition as defined in Claim 3, wherein said mammalianized CETP is a humanized rabbit CETP. 5. A vaccine composition as defined in Claim 4, wherein said humanized rabbit CETP has the amino acid sequence of SEQ ID NO. 5. 6. A vaccine composition as defined in Claim 1, wherein said mammal is a rabbit and said non-endogenous CETP is human CETP. 7. A vaccine composition as defined in Claim 1 or 3, which contains an adjuvant selected from the group consisting of alum, Freund's Complete Adjuvant, Freund's Incomplete Adjuvant, REBI Adjuvant System. 8. A plasmid-based vaccine comprising a promoter sequence suitable for directing the transcription of a nucleotide sequence in a cell of a mammal operably linked to a nucleotide sequence coding for a cholesteryl ester transfer protein (CETP) that is non-endogenous to s τ " d mammal. 9. A plasmid-based vaccine as defined in Claim 8, wherein said mammal is a human and said non-endogenous CETP is selected from the group consisting of rabbit CETP, mouse CETP, simian CETP, humanized rabbit, mouse or simian CETP, and allelic variants or polymorphs of said human's CETP. 10. A plasmid-based vaccine as defined in Claim 8, wherein said mammal is a human and said non-endogenous CETP is rabbit CETP. 11. A plasmid-based vaccine as defined in Claim 8, wherein said mammal is a human and said non-endogenous CETP is a humanized rabbit CETP. 12. A plasmid-based vaccine as defined in Claim 11 , wherein said non-endogenous CETP has the amino acid sequence of SEQ ID NO: 5. 13. A plasmid-based vaccine as defined in Claim 8, wherein said mammal is a rabbit and said non-endogenous CETP is a human CETP. 14. A plasmid-based vaccine as defined in Claim 8, wherein the promoter is the cytomegalovirus immediate early promoter/enhancer. 15. A method for promoting production in a mammal of antibodies binding the mammal's endogenous CETP comprising administering to the mammal a non-endogenous CETP or a mammalianized non-endogenous CETP, optionally in combination with an adjuvant effective to non-specifically stimulate the immune response of said mammal. 16. A method for elevating the ratio of circulating high density lipoprotein-associated cholesterol to circulating low density lipoprotein-associated cholesterol or total cholesterol in a mammal comprising administering to the mammal a non-endogenous CETP or a mammalianized non-endogenous CETP, optionally in combination with an adjuvant effective to non-specifically stimulate the immune response of said mammal. 17. A method for decreasing the level of endogenous CETP activity in a human or other animal comprising administering to the mammal a non-endogenous CETP or a mammalianized non-endogenous CETP, optionally in combination with an adjuvant effective to non-specifically stimulate the immune response of said mammal. 18. A method for altering the metabolism of low density lipoprotein-associated cholesterol to decrease the development of atherosclerotic lesions in a mammal comprising administering to the mammal a non-endogenous CETP or a mammalianized non-endogenous CETP, optionally in combination with an adjuvant effective to non-specifically stimulate the immune response of said mammal. 19. A method of lowering the level of circulating low density lipoprotein in a mammal comprising administering to the mammal a non-endogenous CETP or a mammalianized non- endogenous CETP, optionally in combination with an adjuvant effective to non-specifically stimulate the immune response of said mammal. 20. A method of lowering the level of total circulating cholesterol in a mammal comprising administering to the mammal a non-endogenous CETP or a mammalianized non- endogenous CETP, optionally in combination with an adjuvant effective to non-specifically stimulate the immune response of said mammal. 21. A method for therapeutically or prophylactically treating atherosclerosis in a mammal comprising administering to the mammal a non-endogenous CETP or a mammalianized non- endogenous CETP, optionally in combination with an adjuvant effective to non-specifically stimulate the immune response of said mammal. 22. A method according to any of Claims 15-21, wherein the mammal is a human and the non-endogenous CETP is a rabbit CETP. 23. A method according to any of Claims 15-21, wherein said mammalianized CETP is A humanized rabbit CETP. 24. A method according to Claim 23, wherein said humanized rabbit CETP has the amino acid sequence of SEQ ID NO. 5. 25. A method according to any of Claims 15-21, wherein said CETP is administered in combination with an adjuvant selected from the group consisting of alum, Freund's Complete Adjuvant, Freund's Incomplete Adjuvant, REBI Adjuvant System. 26. A method for promoting production in a mammal of antibodies reactive with the mammal's endogenous CETP comprising fransfecting at least one cell of the mammal with a plasmid-based vaccine according to Claim 8. 27. A method for elevating the ratio of circulating high density lipoprotein-associated cholesterol to circulating low density lipoprotein-associated cholesterol or total cholesterol in a mammal comprising transfecting at least one cell of the mammal with a plasmid-based vaccine according to Claim 8. 28. A method for decreasing the level of endogenous CETP activity in a human or other animal comprising transfecting at least one cell of the mammal with a plasmid-based vaccine according to Claim 8. 29. A method for altering the metabolism of low density lipoprotein-associated cholesterol to decrease the development of atherosclerotic lesions in a mammal comprising transfecting at least one cell of the mammal with a plasmid-based vaccine according to Claim 8. 30. A method of lowering the level of circulating low density lipoprotein in a mammal comprising transfecting at least one cell of the mammal with a plasmid-based vaccine according to Claim 8. 31. A method of lowering the level of total circulating cholesterol in a mammal comprising transfecting at least one cell of the mammal with a plasmid-based vaccine according to Claim 8. 32. A method for therapeutically or prophylactically treating atherosclerosis in a mammal comprising transfecting at least one cell of the mammal with a plasmid-based vaccine according to Claim 8. 33. A method according to any of Claims 26-32, wherein the mammal is a human and the plasmid-based vaccine includes nucleic acid encoding a rabbit CETP. 34. A method according to any of Claims 26-32, wherein the mammal is a human and the plasmid-based vaccine includes nucleic acid encoding a humanized rabbit CETP. 35. A method according to Claims 34, wherein said humanized rabbit CETP has the amino acid sequence of SEQ ED NO. 5. 36. A method according to any of Claims 26-32, which comprises the additional step of administering to said mammal an adjuvant effective to non-specifically stimulate the immune response of said mammal. 37. A method according to Claim 36, wherein the adjuvant is selected from the group consisting of alum, Freund's Complete Adjuvant, Freund's Incomplete Adjuvant, RIBI Adjuvant System.

Inventors: RITTERSHAUS CHARLES W, THOMAS LAWRENCE J, RITTERSHAUS, CHARLES, W., THOMAS, LAWRENCE, J.
Applicants: AVANT IMMUNOTHERAPEUTICS INC, RITTERSHAUS CHARLES W, THOMAS LAWRENCE J, AVANT IMMUNOTHERAPEUTICS, INC., RITTERSHAUS, CHARLES, W., THOMAS, LAWRENCE, J.
Application year: 1998
Main classification: A61K39
IPC codes: A61K39, A61K48, A61P9, A61P37, C07K14, C12N15